Estraval Depot (Estradiol Valerate) 10 mg/ml: Hormonal Architecture for Female Health and Feminizing Therapy

The endocrine system is an exquisitely tuned orchestra, and estrogens serve as its first-chair violins in regulating the reproductive cycle, bone metabolism, and the psycho-emotional landscape of a woman’s health. Estraval Depot is an oil-based solution for intramuscular injection containing 10 mg/ml of estradiol valerate. Manufactured by India’s Actiza Pharmaceutical Ltd and packaged in 10 glass ampoules, its sustained-release formulation sustains a stable hormonal milieu over the course of weeks, positioning it as a tool of choice across highly diverse clinical scenarios — from menstrual dysfunction correction to feminizing hormone therapy programs.

🧬 Biochemical Essence and the Principle of Depot Action

Estradiol represents the most potent natural estrogen synthesized by the ovarian follicular apparatus. In its unmodified state, it possesses a short half-life, hence its valerate ester is employed to create a therapeutic depot. Once deposited into the muscle, the formulation establishes a micro-reservoir from which active estradiol is gradually liberated via enzymatic cleavage of the valeric acid moiety. This design achieves:

• A smooth, peak-and-trough-free hormonal background spanning 1–4 weeks.
• Reduced injection frequency, thereby enhancing patient compliance.
• A physiological mode of action, closely mirroring the rhythm of endogenous estradiol.

📋 Map of Clinical Indications

Estraval Depot’s clinical remit encompasses a broad array of pathologies rooted in estrogen deficiency or imbalance:

1. Menstrual Cycle Disturbances:

• Primary and secondary amenorrhea (absence of menstruation).
• Oligomenorrhea (excessively infrequent cycles).
• Polymenorrhea (abnormally frequent menstruation).
• Volume abnormalities: both scanty and excessively heavy blood loss.
• Dysmenorrhea — painful menstruation that markedly erodes quality of life.

2. Organic Pathology:

• Functional uterine bleeding unrelated to a neoplastic process.
• Uterine hypoplasia (underdevelopment of the organ), wherein estrogen support stimulates myometrial and endometrial growth.

3. Menopausal Transition and Involution:

• Symptoms of estrogen deficiency during perimenopause and postmenopause: vasomotor flushes, urogenital atrophy, emotional lability, and osteoporosis.

4. Reproductive Technologies:

• Endometrial preparation for implantation within in-vitro fertilization (IVF) protocols.
• Management of certain infertility forms linked to luteal phase insufficiency or a chronically thin endometrium.

5. Feminizing Hormone Therapy (MtF Gender Transition):

• Estradiol valerate holds a central place in hormonal correction regimens for transgender women. Its goals are to suppress endogenous testosterone production and induce the development of female secondary sexual characteristics: breast growth, adipose tissue redistribution toward a gynoid pattern, skin texture alteration, and softening of androgen-dependent features.

💉 Administration Protocol and Dosing Regimen

• Route of Administration: Strictly intramuscular, typically into the gluteal muscle. The injection must be performed by a healthcare professional adhering to aseptic technique.
• Dose Range: 5–10 mg of estradiol valerate (0.5–1 ml of solution) administered once every 1–4 weeks.
• Individualization: The precise dose and inter-injection interval are titrated by the physician, taking into account the target hormonal profile, clinical response, tolerability, and the specific indication — be it menopausal therapy, IVF preparation, or transgender transition.

⚠️ Absolute Contraindications and Red Flags

Estrogen therapy carries significant risks in the presence of the following conditions:

• Estrogen-Dependent Malignancies: Breast cancer, endometrial cancer (including a history of either).
• Untreated Endometrial Hyperplasia, given the threat of malignant transformation.
• Venous Thromboembolic Events: Thrombophlebitis, deep vein thrombosis, pulmonary embolism (including past occurrences).
• Arterial Thromboembolism: Coronary artery disease, myocardial infarction, or stroke in the patient’s history.
• Severe Hepatic Failure: Impaired estrogen metabolism intensifies the toxic burden on hepatocytes.
• Undiagnosed Abnormal Uterine Bleeding — until the etiology is fully clarified.
• Pregnancy and Lactation: The product is contraindicated. Estrogens cross the placental barrier and enter breast milk, with the potential to harm the fetus or the nursing infant.

📊 Safety Profile and Drug-Drug Interactions

Before commencing therapy, the patient must inform the physician of:

• Any history of drug allergies.
• The presence of renal insufficiency.
• A complete list of all concurrently taken medications (including over-the-counter items) due to the risk of pharmacokinetic interactions.

Regular clinical and laboratory monitoring is mandatory throughout treatment. Any unusual symptoms — allergic rashes, unscheduled bleeding, lower limb pain, or sudden breathlessness — must be reported to the physician without delay.

📦 Storage Conditions

Ampoules must be retained inside the original manufacturer’s carton, in a dark, cool, and dry location, securely out of children’s reach. Direct sunlight exposure is detrimental to the stability of the active ingredient.

📦Find out about the delivery to your country on WhatsApp